SPAC Feed

CALGARY, AB, July 21, 2026 (GLOBE NEWSWIRE) — Seegnal Inc. (TSXV: SEGN) (“Seegnal” or the “Company”), a global leader in SaaS clinical division support solutions, is announcing an extension to its previously announced non-brokered private placement on June 2, 2026 (the “Offering”) of up to 4,642,857 units in the capital of the Company (each, a “Unit”) for gross proceeds of up to CDN$1,300,000, at a price of $0.28 per Unit. Each Unit is comprised of one common share in the capital of the Company (each, a “Common Share”) and one common share purchase warrant (each, a “Warrant”). Each Warrant is exercisable to acquire one Common Share at a price of CDN$0.50 for a period of 36 months.

Houston, TX, July 21, 2026 (GLOBE NEWSWIRE) — CO2 Energy Transition Corp. (Nasdaq: NOEM) today announced that shareholders have approved all of the proposals that were considered at the shareholder meeting that took place today including a proposal to extend the deadline by which the SPAC must complete its initial business combination. This will allow the opportunity for the Company to negotiate and enter into definitive agreements for the proposed business combination with the critical mineral target company that was announced on July 17, 2026.

Aberdale brings over two decades of entrepreneurial scaling, public market and private sale experience, and operational leadership to accelerate the clinical and commercial deployment of AiM’s dynamic image-guided neurosurgery system.

The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

The PD-1 and PD-L1 inhibitors competitive landscape report delivers important insights into approved as well as ongoing research of 200+ pipeline PD-1 and PD-L1 inhibitor drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the market growth.

The head and neck squamous cell carcinoma market is experiencing significant growth, driven by the rising incidence of head and neck cancers worldwide, increasing adoption of immunotherapies, targeted therapies, and combination treatment approaches. Additionally, the expected launch of emerging therapies such as Amivantamab (RYBREVANT) (Johnson & Johnson), BNT113 (BioNTech), Petosemtamab (MCLA-158) (Genmab), Eftilagimod Alfa (Immutep), and others will further propel the market growth.

Market uncertainty and lack of confidence are keeping Canadians on the sidelines, a new Tangerine survey finds.

Market uncertainty and lack of confidence are keeping Canadians on the sidelines, a new Tangerine survey finds.

Lesquin, 21 July 2026, 6:00 pm

Lesquin, 21 juillet 2026, 18h00

Paris Forino Shares the Design Approach Behind Today’s Most Successful Residential Developments

Paris Forino Shares the Design Approach Behind Today's Most Successful Residential Developments

In a Fast-Track Swift challenge brought by Human Power of N Company (Humann), BBB National Programs’ National Advertising Division found that Force Factor Brands LLC substantiated its claims that Total Beets® is “America’s #1 Best-Selling Beets Brand,” the “#1 Best Selling Beets Brand in America,” and the “#1 Beets Brand in America” based on unit sales data. However, the National Advertising Division (NAD) recommended that Force Factor modify the claim “#1 Beets Brand in America” to disclose that the ranking is based on total unit sales.

In a Fast-Track Swift challenge brought by Human Power of N Company (Humann), BBB National Programs’ National Advertising Division found that Force Factor Brands LLC substantiated its claims that Total Beets® is “America’s #1 Best-Selling Beets Brand,” the “#1 Best Selling Beets Brand in America,” and the “#1 Beets Brand in America” based on unit sales data. However, the National Advertising Division (NAD) recommended that Force Factor modify the claim “#1 Beets Brand in America” to disclose that the ranking is based on total unit sales.

ZetaDisplay has been selected by Media Port to deliver the commerce media platform for Copenhagen Airport, launching in 2027.

The U.S. Multiplex Assays Market is projected to grow from USD 1.12 Billion in 2025 to USD 2.65 Billion by 2035, while Europe is expected to expand from USD 0.96 Billion to USD 2.47 Billion, driven by increasing adoption of multiplex PCR, flow cytometry, and precision diagnostics.

The U.S. Multiplex Assays Market is projected to grow from USD 1.12 Billion in 2025 to USD 2.65 Billion by 2035, while Europe is expected to expand from USD 0.96 Billion to USD 2.47 Billion, driven by increasing adoption of multiplex PCR, flow cytometry, and precision diagnostics.